Premium
Doxorubicin and cyclophosphamide‐induced parotitis: A case report
Author(s) -
FoxLewis Andrew,
Tairab Mohammed,
Fulton Graham,
KuperHommel Marion,
Jameson Michael B.
Publication year - 2020
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.13048
Subject(s) - parotitis , cyclophosphamide , doxorubicin , medicine , chemotherapy , surgery
What is known and objective Drug‐induced parotitis is a rare adverse drug reaction (ADR). A comprehensive literature review identified only three clearly associated medications: L‐asparaginase, clozapine and phenylbutazone. Case description We describe a novel case of drug‐induced parotitis attributed to doxorubicin and cyclophosphamide chemotherapy for breast cancer. What is new and conclusion Using general and parotitis‐specific tools for assessing the probability of an ADR, we estimate the association of doxorubicin and cyclophosphamide with parotitis in this case as ‘probable’. To our knowledge, this represents the first reported case of parotitis attributable to these medications and provides a valuable learning tool for the assessment of previously unrecognized ADRs.